Hemastatx

Hemastatx email format

Verified email-pattern data for Hemastatx is currently limited. You can still use the company insights and contact sections below.
Hemastatx is committed to bringing scientific innovation to patients with severe and underserved bleeding disorders, aiming to become a leader in hematology. Founded in 2025 as a spin-off from KU Leuven, Hemastatx builds on over a decade of pioneering research in hemostasis at the Laboratory for Thrombosis Research, led by Prof. dr. Karen Vanhoorelbeke. Our first lead program, HMX-001, is a proprietary monoclonal antibody designed to stop bleeding in patients with von Willebrand factor (VWF)-related disorders by targeting the underlying biological mechanism. The program is supported by a robust preclinical data package and broad patent protection. With headquarters in Switzerland and an R&D hub in Belgium, Hemastatx is strategically positioned within two of Europe’s leading biotech ecosystems.

Company Details

Employees
2
Founded
-
Address
Hegenheimermattweg 167a, Allschwil,basel-Country 4123,switzerland
Industry
Biotechnology Research
HQ
Allschwil, Basel-Country
Looking for a particular Hemastatx employee's phone or email?

Hemastatx Questions

Explore related pages

Related company profiles:

Top Hemastatx Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant